AACR commits to Love/Avon Army of Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

The American Association for Cancer Research will provide scientific expertise to Love/Avon Army of Women, an organization that seeks to link more than one million women volunteers with cancer researchers across the country to discover breast cancer causes and to aid in prevention.

The American Association for Cancer Research will provide scientific expertise to Love/Avon Army of Women, an organization that seeks to link more than one million women volunteers with cancer researchers across the country to discover breast cancer causes and to aid in prevention.

AACR member physicians and scientists working in the field of breast cancer research will occupy eight seats on the scientific advisory committee and one seat on the steering committee. The AACR will assist in decision making regarding the policies, direction, and vision of the project as well as in the review of requests from scientists seeking permission to solicit volunteers from the Love/Avon Army of Women for their breast cancer research studies.

Only investigators who have a peer-reviewed study will gain access to volunteers in the Love/Avon Army of Women. Each study will undergo a thorough scientific, safety and ethical review by expert scientists.

The AACR will use its major scientific meetings and its journal Cancer Prevention Research as forums to present the research.

Women interested in participating in this effort may enroll at www.armyofwomen.org. Healthy women of every age and ethnicity are eligible.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.